Become a partner

CAMP + IndiCell tour on pluripotent stem cells

Learn about activities in Sweden toward development and commercialisation of pluripotent derived ATMPs!

The Center for Advanced Medical Products (CAMP) and the innovations milieu IndiCell welcomes you to a webinar on pluripotent stem cells and their applications for advanced therapy medicinal products (ATMP).

Date: June 2nd 2022, at 13:00-15:00 (local Swedish time)

Zoom webinar, register to receive link.

This is a satellite webinar to the ATMP world tour with special focus on Sweden´s position in pluripotent stem cells.

 

Agenda

13:00 Welcome – Heather Main, moderator 

13:05 Cell therapies, history, basic science and CAMP – Anders Lindahl

13:20 Towards translation, iPSC and IndiCell – Anna Falk

13:35 Cont. translation, automated manufacture, clinical use – Malin Parmar

13:50 Cont. translation, manufacture, clinical use – Fredrik Lanner

14:05 Society, patient groups, value survey on embryonic stem cells– Mats Hansson

14:20 Panel discussion (all presenters + Heather)

15.00 Webinar ends

Who are the presenters?

Anders Lindahl – Anders is a senior researcher at the University of Gothenburg with extensive experience in cell therapies, ATMP development and pluripotent stem cells. Anders is a member of CAMP executive board and the steering group of VOG Cell.

Anna Falk – Anna is a professor in neural stem cells at Lund University. Her lab has derived an hiPSC line in the GMP facility Vecura, Stockholm, Sweden. Anna coordinates IndiCell together with Malin Parmar and Fredrik Lanner.

Malin Parmar – Malin is a professor in Developmental and Regenerative Neurobiology at Lund University and a Robertson Investigator at the New York Stem Cell Foundation. Her lab has developed the method for manufacture of hPSC derived dopaminergic neuron progenitors for treatment of Parkinson’s disease. The product is being manufactured at Royal Free Hospital, London, UK.

Fredrik Lanner – Fredrik is an assistant professor at Karolinska Institutet. His lab has developed the method for manufacture of hPSC derived retinal pigment epithelia for treatment of dry Age related Macular Degeneration. The product is being manufactured by Fredrik’s staff at Vecura, Stockholm, Sweden and is Sweden’s first hPSC-ATMP.

Mats Hansson – Mats is Senior Professor and the former director of the Centre for Research Ethics & Bioethics at Uppsala Universitet. He has conducted extensive research in biomedical ethics and has long experience in dealing with issues ranging from ethical, social and legal aspects of genetic diagnosis in clinical practice and the use of human tissue materials in research. Mats has led a research project within CAMP, including a value survey on the use of embryonic stem cells in research and product development.